These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1369148)

  • 1. Characterization of two differently glycosylated molecular species of yeast-derived hepatitis B vaccine carrying the pre-S2 region.
    Kobayashi M; Asano T; Ohfune K; Kato K
    J Biotechnol; 1992 Nov; 26(2-3):155-62. PubMed ID: 1369148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis in yeast of hepatitis B virus surface antigen modified P31 particles by gene modification.
    Itoh Y; Fujisawa Y
    Biochem Biophys Res Commun; 1986 Dec; 141(3):942-8. PubMed ID: 3028394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2 + S) protein particles.
    Hazama M; Takaoki M; Ohfune K; Hinuma S; Fujisawa Y
    Vaccine; 1989 Dec; 7(6):567-73. PubMed ID: 2532813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein.
    Yamada T; Iwabuki H; Kanno T; Tanaka H; Kawai T; Fukuda H; Kondo A; Seno M; Tanizawa K; Kuroda S
    Vaccine; 2001 Apr; 19(23-24):3154-63. PubMed ID: 11312011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
    Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
    Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
    Kuroda S; Fujisawa Y; Iino S; Akahane Y; Suzuki H
    Vaccine; 1991 Mar; 9(3):163-9. PubMed ID: 1828318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display.
    Zhang WY; Wan Y; Li DG; Tang Y; Zhou W
    Cell Res; 2001 Sep; 11(3):203-8. PubMed ID: 11642405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein.
    Itoh Y; Kuroda S; Miyazaki T; Otaka S; Fujisawa Y
    J Biotechnol; 1992 Mar; 23(1):71-82. PubMed ID: 1369362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hepatitis B virus surface antigen P31 gene in yeast.
    Itoh Y; Hayakawa T; Fujisawa Y
    Biochem Biophys Res Commun; 1986 Jul; 138(1):268-74. PubMed ID: 2427075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.
    Schmitt S; Glebe D; Alving K; Tolle TK; Linder M; Geyer H; Linder D; Peter-Katalinic J; Gerlich WH; Geyer R
    J Biol Chem; 1999 Apr; 274(17):11945-57. PubMed ID: 10207016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice.
    Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
    Vaccine; 1999 Jun; 17(20-21):2528-37. PubMed ID: 10418899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
    Fujisawa Y; Kuroda S; Van Eerd PM; Schellekens H; Kakinuma A
    Vaccine; 1990 Jun; 8(3):192-8. PubMed ID: 2363298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
    Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
    J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
    Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
    Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen.
    Douvin C; Simon D; Charles MA; Deforges L; Bierling P; Lehner V; Budkowska A; Dhumeaux D
    Diabetes Care; 1997 Feb; 20(2):148-51. PubMed ID: 9118762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg.
    Milich DR; McLachlan A; Chisari FV; Kent SB; Thorton GB
    J Immunol; 1986 Jul; 137(1):315-22. PubMed ID: 2423607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oligosaccharides in a recombinant hepatitis B virus surface antigen (HBsAg) carrying the pre-S2 region derived from yeast.
    Kobayashi M; Ban J; Asano T; Utsunomiya M; Kusumoto S; Nishi K; Kato K
    FEBS Lett; 1992 May; 302(2):129-32. PubMed ID: 1633844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization.
    Coursaget P; Adamowicz P; Bourdil C; Yvonnet B; Buisson Y; Barrès JL; Saliou P; Chiron JP; Mar ID
    Vaccine; 1988 Aug; 6(4):357-61. PubMed ID: 2973189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pepsin digestion in relation to the pre-S region on hepatitis B surface antigen-induced hypersensitivity.
    Lei HY; Wang YL; Lee SC; Chen SH
    J Immunol; 1992 Jun; 148(11):3560-6. PubMed ID: 1375249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.
    Skrastina D; Bulavaite A; Sominskaya I; Kovalevska L; Ose V; Priede D; Pumpens P; Sasnauskas K
    Vaccine; 2008 Apr; 26(16):1972-81. PubMed ID: 18343539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.